<DOC>
	<DOCNO>NCT00532701</DOCNO>
	<brief_summary>Treatment peginterferon plus daily low dose ( 800 mg ) weight-based ribavirin ( 800-1400 mg ) 24 48 week achieve 70-93 % sustain virologic response ( SVR ) rate patient genotype 2 3 chronic hepatitis C ( CHC ) . Recently , large randomize study show patient genotype 2 3 CHC comparable SVR rate receive peginterferon 24 48 week , receive daily low dose ( 800 mg ) standard dose ( 1000-1200 mg ) ribavirin . Therefore , currently recommend treatment patient 24 week peginterferon plus low dose ribavirin . Because high response rate , several study show patient rapid virologic response ( RVR ) , define undetectable hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) level , week 4 peginterferon plus weight-based ribavirin , 12-16 week treatment could 82-94 % SVR rate . However , treatment peginterferon plus low dose ribavirin 24 week show significantly high SVR rate 16 week ( 85 % versus 79 % ) patient achieve RVR . While study show concordant result SVR rate patient genotype 3 CHC receive peginterferon plus low dose weight-based ribavirin 16 24 week , SVR rate stratify RVR show great difference patient genotype 2 CHC receive treatment . Currently , study direct comparison low dose versus weight-based ribavirin , 16 24 week treatment stratify RVR patient genotype 2 CHC . The investigator aim conduct randomize trial determine optimal ribavirin dose treatment duration peginterferon plus ribavirin patient genotype 2 CHC base RVR study .</brief_summary>
	<brief_title>Peginterferon Alfa-2a Ribavirin Genotype 2 Chronic Hepatitis C : Duration Ribavirin Dose Stratified RVR</brief_title>
	<detailed_description>Treatment peginterferon plus daily low dose ( 800 mg ) weight-based ribavirin ( 800-1400 mg ) 24 48 week achieve 70-93 % sustain virologic response ( SVR ) rate patient genotype 2 3 chronic hepatitis C ( CHC ) . Recently , large randomize study show patient genotype 2 3 CHC comparable SVR rate receive peginterferon 24 48 week , receive daily low dose ( 800 mg ) standard dose ( 1000-1200 mg ) ribavirin . Therefore , currently recommend treatment patient 24 week peginterferon plus low dose ribavirin . Because high response rate , several study show patient rapid virologic response ( RVR ) , define undetectable hepatitis C virus ( HCV ) RNA level , week 4 peginterferon plus weight-based ribavirin , 12-16 week treatment could 82-94 % SVR rate . However , treatment peginterferon plus low dose ribavirin 24 week show significantly high SVR rate 16 week ( 85 % vs. 79 % ) patient achieve RVR . While study show concordant result SVR rate patient genotype 3 CHC receive peginterferon plus low dose weight-based ribavirin 16 24 week , SVR rate stratify RVR show great difference patient genotype 2 CHC receive treatment . Currently , study direct comparison low dose versus weight-based ribavirin , 16 24 week treatment stratify RVR patient genotype 2 CHC . We aim conduct randomize trial determine optimal ribavirin dose treatment duration peginterferon plus ribavirin patient genotype 2 CHC base RVR study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Treatment na√Øve Age old 18 year old AntiHCV ( Abbott HCV EIA 2.0 , Abbott Diagnostic , Chicago , IL ) positive &gt; 6 month Detectable serum quantitative HCVRNA ( Cobas Taqman HCV Monitor v2.0 , Roche Diagnostics ) dynamic range 25 ~ 391000000 IU/ml HCV genotype 2 ( InnoLiPA HCV II , Innogenetics , Ghent , Belgium ) Serum alanine aminotransferase level upper limit normal 6 month enrollment A liver biopsy consistent diagnosis chronic hepatitis C Anemia ( hemoglobin &lt; 13 gram per deciliter men &lt; 12 gram per deciliter woman ) Neutropenia ( neutrophil count &lt; 1,500 per cubic milliliter ) Thrombocytopenia ( platelet &lt; 90,000 per cubic milliliter ) Coinfection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Chronic alcohol abuse ( daily consumption &gt; 20 gram per day ) Decompensated liver disease ( ChildPugh class B C ) Serum creatinine level 1.5 time upper limit normal Autoimmune liver disease Neoplastic disease An organ transplant Immunosuppressive therapy Poorly control autoimmune disease , pulmonary disease , cardiac disease , psychiatric disease , neurological disease , diabetes mellitus Evidence drug abuse Unwilling use contraception Unwilling sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Genotype</keyword>
	<keyword>Interferon</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Peginterferon</keyword>
</DOC>